Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01627288
Study type Interventional
Source Duke University
Contact
Status Completed
Phase N/A
Start date June 4, 2012
Completion date November 16, 2019

See also
  Status Clinical Trial Phase
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Recruiting NCT03403465 - Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Phase 2
Completed NCT01536392 - Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Phase 3
Completed NCT00510250 - A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer Phase 1/Phase 2
Not yet recruiting NCT05521997 - Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Phase 2
Active, not recruiting NCT02328872 - Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia N/A
Recruiting NCT00292955 - Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Phase 2
Terminated NCT03318107 - Ultrasound and Photoacoustic Imaging for Cervical Cancer N/A
Recruiting NCT00122746 - Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients Phase 3
Recruiting NCT05975593 - MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Recruiting NCT04868097 - Predicting Adjuvant Post-operative Radiation Therapy in Patients With Cervical Cancer Stage IB2 N/A